Ibsrela / Xphozah (Tenapanor)

Tenapanor is a pill that treats two different problems. As Ibsrela, it helps adults with irritable bowel syndrome that causes constipation; as Xphozah, it lowers high phosphate levels in adults on kidney dialysis. It works in the gut, keeping more water in the bowel and letting less phosphate into the blood.

Brand names:Ibsrela, Xphozah
Medication

What people taking Ibsrela / Xphozah (Tenapanor) report

Every report comes from a Lived member, sent anonymously.

Have you tried Ibsrela / Xphozah (Tenapanor) for IBS (Irritable Bowel Syndrome)?

NameHow it went

About Ibsrela / Xphozah (Tenapanor)

What It's For

Tenapanor is a prescription tablet sold under two brand names for two unrelated problems. Ibsrela treats irritable bowel syndrome with constipation (IBS-C) in adults, a long-term gut condition in which abdominal pain or discomfort comes with hard, infrequent or difficult bowel movements. Xphozah lowers blood phosphorus in adults with chronic kidney disease who are on dialysis. For IBS-C, tenapanor is one of several prescription options. The American Gastroenterological Association gives it a conditional recommendation, meaning it is a reasonable choice for many people but not a clear first pick for everyone; linaclotide (Linzess), another prescription IBS-C medicine that draws water into the bowel, has a strong recommendation, meaning the panel was more confident it helps most people. Other prescription medicines and over-the-counter laxatives are also options. Xphozah is not usually a first step for phosphorus. It is meant for people whose phosphorus stays too high despite phosphate binders (medicines taken with meals that hold phosphorus from food in the gut so it leaves in the stool), or who cannot tolerate binders at any dose. It can be added to a binder or used when binders are not an option. The two brands contain the same active ingredient but come in different strengths with different instructions, so one should not be used in place of the other.

How It Works

Tenapanor works inside the intestine and very little of it reaches the bloodstream. It blocks a protein called NHE3 (sodium/hydrogen exchanger 3) on the lining of the small intestine and colon, which normally pulls sodium from digested food into the body. When less sodium is absorbed, more water stays in the bowel. In IBS-C, that softens stool and moves it along faster. Animal studies suggest it may also make the gut less sensitive to pain, which could help explain why abdominal pain improves for some people, though this has not been confirmed in humans. Blocking NHE3 also makes it harder for phosphate from food to pass between the cells lining the gut, so less of it reaches the blood. That is the effect used in kidney failure. When the kidneys have failed, phosphorus from food builds up in the blood between dialysis sessions. High phosphorus pulls calcium out of the bones, weakening them, and can cause itching. Unlike binders, which soak up phosphate, tenapanor reduces the route phosphate takes to get absorbed.

Dosage & Administration

Both brands are tablets taken twice a day, just before breakfast (or the first meal of the day) and just before the evening meal. In studies, taking it 5 to 10 minutes before a meal increased its effect compared with taking it with food or on an empty stomach. Ibsrela comes as a single 50 mg strength for adults with IBS-C. Xphozah comes in 10, 20 and 30 mg strengths; the usual starting dose is 30 mg twice daily, and the care team may lower it if diarrhea is a problem, using regular blood phosphorus results to guide changes. People on hemodialysis should not take Xphozah right before a dialysis session, because diarrhea during a session is a real risk. Instead, they take that dose just before the next meal after dialysis. If a dose is missed, skip it and take the next one at the usual time. Do not take two doses together.

Side Effects

Diarrhea is by far the most common side effect, and it is the main reason people stop. In the IBS-C trials, about 15 to 16 out of every 100 people taking Ibsrela had diarrhea, compared with 2 to 4 on placebo. Among people on dialysis taking Xphozah, roughly half had diarrhea. It usually starts soon after beginning treatment, is mostly mild to moderate, and often settles over time or with a lower dose. Bloating, gas and dizziness are also reported with Ibsrela. Severe diarrhea occurred in about 2 to 3 out of 100 people with IBS-C and about 5 out of 100 people on dialysis. If diarrhea becomes severe, stop taking tenapanor and contact the prescriber promptly. Drinking fluids to replace what is lost matters. People on dialysis should ask their care team how to do this within their fluid limits. Rarely, severe diarrhea has led to dehydration or low sodium levels. Itching, rash and hives have been reported with tenapanor (both brands) after approval.

Interactions & Warnings

Tenapanor must not be given to children under 6, and it should be avoided in children aged 6 to under 12. In young animals it caused deaths from dehydration, and it has not been shown to be safe or effective in anyone under 18. Ibsrela carries a boxed warning, the most prominent warning the US Food and Drug Administration (FDA) puts on a label, about this risk. It should not be used by anyone with a known or suspected bowel blockage. Because it acts in the gut, tenapanor can reduce how well some other medicines are absorbed. The best studied example is enalapril, a blood pressure medicine, whose levels fell by half or more; blood pressure may need closer checks. People taking Xphozah with sodium polystyrene sulfonate, a medicine used to lower high potassium, should space the two at least 3 hours apart. Share a full medicine list with the prescriber and pharmacist. So little tenapanor enters the blood that it is not expected to reach a developing baby or breast milk, though human data in pregnancy are limited.

What to Expect

For IBS-C, people who respond often notice more frequent, easier bowel movements and less abdominal pain within the first week or two. Not everyone responds: in the main trials, about 27 to 37 out of 100 people met a combined goal of better bowel movements and at least 30 percent less pain in at least half of the weeks, compared with 19 to 24 out of 100 on placebo. When people stopped, symptoms tended to drift back. It is generally a continuing treatment rather than a short course, and a lack of benefit after a few weeks is a reason to discuss other options. For people on dialysis, Xphozah lowered blood phosphorus by about 0.7 mg/dL more than placebo when added to binders. For scale, a normal adult level is about 2.8 to 4.5 mg/dL, renal teams generally aim to bring high levels down toward that range, and people in the trials started at 5.5 mg/dL or higher despite binders. A drop of about 0.7 mg/dL is a modest extra reduction: it can help some people reach their target alongside binders and diet, but on its own it usually does not close the whole gap. The renal team checks phosphorus with routine dialysis bloodwork and adjusts the dose, binders and diet together. Tenapanor does not replace the low-phosphorus eating plan, and many people still need a binder as well.

Questions to Ask Your Doctor

  1. 1.Why is tenapanor a better fit for me than other IBS-C treatments, such as linaclotide or a laxative?
  2. 2.How soon should I expect a change, and what would make us decide it isn't working?
  3. 3.What should I do if diarrhea starts, and when should I stop the medicine and call you?
  4. 4.If I take Xphozah, how should I time doses around dialysis and my phosphate binder?
  5. 5.Do any of my other medicines need monitoring or dose changes while I take tenapanor?

Last reviewed • Oct 2026

Educational content, not medical advice.